Skip to main content
JAZZJazz Pharmaceuticals plcBuy Wait6.6·$247.00-0.23%

Jazz Pharmaceuticals (JAZZ) Q2 2026 earnings — TrendMatrix coverage

MISS-7.5% vs estimateEPS $5.71 vs $6.18 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$5.71
Estimate
$6.18
Surprise
-7.5%
Revenue (period 2026-06-30)
$1.21B
Score at report (before → after)
6.36.3/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Jazz Pharmaceuticals (JAZZ) missed the $6.18 estimate with diluted EPS of $5.71 — a clear 7.5% shortfall. TrendMatrix's engine moved from Buy (Wait) (6.3/10) to Hold at 6.3/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates JAZZ Buy (Wait) at 6.6/10.

3 of the last 4 quarters beat the estimate; this quarter's -7.5% surprise compares with a +17.4% four-quarter average. Next scheduled report: 2026-11-04.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Supplier: ESSDS
  • Thin upside margin: 5.5%
  • Negative momentum

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$247.00
Entry target
$235.47
Price target
$260.50
Stop
$219.86
Upside to target
+5.5%
Reward-to-risk
0.9:1

The stock trades at 17.0× trailing but 9.6× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

JAZZ at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$16.07B
P/E (fwd)
9.6
P/E (ttm)
17.0
52-week range
$123.88$266.38
Off 52-week high
7.3%
RSI (14)
49
Volume vs avg
0.05×
Score today
6.6/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks JAZZ Earnings Q2 2026 earnings